Equities Analysts Issue Forecasts for Intersect ENT Inc’s Q1 2018 Earnings (XENT)
Intersect ENT Inc (NASDAQ:XENT) – Analysts at William Blair dropped their Q1 2018 EPS estimates for Intersect ENT in a report released on Wednesday. William Blair analyst K. Krum now forecasts that the medical equipment provider will post earnings of ($0.18) per share for the quarter, down from their previous estimate of ($0.16). William Blair also issued estimates for Intersect ENT’s Q2 2018 earnings at ($0.17) EPS, Q3 2018 earnings at ($0.18) EPS, Q4 2018 earnings at ($0.12) EPS, FY2018 earnings at ($0.66) EPS, Q2 2019 earnings at ($0.11) EPS, Q4 2019 earnings at ($0.07) EPS and FY2019 earnings at ($0.45) EPS.
Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.06. Intersect ENT had a negative net margin of 16.99% and a negative return on equity of 14.55%. The business had revenue of $29.53 million for the quarter, compared to the consensus estimate of $29.45 million.
Intersect ENT (NASDAQ XENT) opened at $35.85 on Monday. The firm has a market cap of $1,068.51, a P/E ratio of -62.89 and a beta of 0.80. Intersect ENT has a 1-year low of $13.60 and a 1-year high of $38.30.
A number of institutional investors and hedge funds have recently made changes to their positions in XENT. Jennison Associates LLC increased its position in Intersect ENT by 22.4% in the fourth quarter. Jennison Associates LLC now owns 2,036,202 shares of the medical equipment provider’s stock worth $65,973,000 after purchasing an additional 372,320 shares during the last quarter. Teachers Advisors LLC increased its position in Intersect ENT by 333.9% in the fourth quarter. Teachers Advisors LLC now owns 288,732 shares of the medical equipment provider’s stock worth $9,355,000 after purchasing an additional 222,195 shares during the last quarter. Alliancebernstein L.P. increased its position in Intersect ENT by 12.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,466,730 shares of the medical equipment provider’s stock worth $47,522,000 after purchasing an additional 161,723 shares during the last quarter. State Street Corp increased its position in Intersect ENT by 33.6% in the second quarter. State Street Corp now owns 552,344 shares of the medical equipment provider’s stock worth $15,437,000 after purchasing an additional 138,968 shares during the last quarter. Finally, OxFORD Asset Management LLP bought a new stake in Intersect ENT in the third quarter worth $2,371,000. Institutional investors own 85.50% of the company’s stock.
In related news, COO Richard E. Kaufman sold 50,000 shares of the business’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $33.33, for a total value of $1,666,500.00. Following the sale, the chief operating officer now owns 107,470 shares in the company, valued at $3,581,975.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel David Aaron Lehman sold 36,000 shares of the business’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $32.75, for a total transaction of $1,179,000.00. Following the completion of the sale, the general counsel now owns 45,000 shares in the company, valued at approximately $1,473,750. The disclosure for this sale can be found here. In the last quarter, insiders have sold 159,477 shares of company stock worth $5,378,277. Company insiders own 13.70% of the company’s stock.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.